AxogenAXGN
Recorded

Axogen 2026 Q2 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ2 2026Duration53 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, everyone. Joining me on today's call is Michael Dale, AxoGen's President and Chief Executive Officer, and Lindsey Hartley, Chief Financial Officer. Michael will discuss second quarter 2026 financial results and corporate highlights. Lindsey will then provide details on financial performance and overall outlook for the year. This will be followed by a question and answer session. Today's call and presentation is being broadcast live via webcast, which is available on the investors section of AxoGen's website. Following the end of the live call, a replay will be available on the investors section of the company's website at www.axogeninc.com. Before we begin, I would like to remind you that during this conference call, management will be making forward-looking statements.

Operator

Forward-looking statements include statements regarding financial guidance and outlook, clinical development and regulatory efforts, commercial growth initiatives, reimbursement and market access efforts, training and education initiatives, research and development activities, and overall business strategy and performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including, without limitation, the risks and uncertainties reflected in the company's filings with the Securities and Exchange Commission, including the most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other filings made with the Securities and Exchange Commission. Forward-looking statements speak only as of the day they are made, and the company undertakes no obligation to update any forward-looking statements except as required by law.

Operator

In addition, for a reconciliation of non-GAAP measures, please refer to today's press release, presentation with highlights from today's call, and the corporate presentation on the investors section of the company's website. Now I'll turn the call over to Michael.

Michael DalePresident and CEO

Michael, please go ahead. Thank you, operator, and good morning, everyone.

Michael DalePresident and CEO

Today, I will walk you through our second quarter performance using the same lens we've used all year, which are the six priorities that comprise our strategic plan. Once I've concluded my commentary, Lindsey will review our financials in detail, after which we'll open the call for questions. As preface to my review of performance for each strategic priority, I want to make clear on behalf of the AxoGen team that we are delighted with our customer creation and market development performance. What you will hear today is that consistent with our plans across extremities, OMF and head and neck, breast, and prostate, we are exceeding our goals for growing adoption of nerve care by existing surgeons, increasing the numbers of new surgeons, expanding the number of new accounts, and growing patient awareness overall.

Michael DalePresident and CEO

Our 23% year-over-year revenue growth this quarter and increased revenue guidance for the remainder of the year reflects this progress and our confidence in the appropriateness of our strategic priorities. While all markets are enjoying strong year-over-year growth, breast growth is particularly strong and accelerating, reflecting the impact of our market development programs, increased patient awareness, improved coverage and payment, and expanded sales force coverage. As a result, we will be reporting on the breast business separately in more detail. Starting with our first priority, revenue growth and financial operating leverage. As reported this morning in our earnings release, second quarter revenue was $69.7 million, up 23.1% versus the second quarter of 2025, reflecting broad-based growth across all three target markets. Breast led the way, contributing approximately two-thirds of the quarter's growth, with first half 2026 revenue up 47% year-over-year.

Michael DalePresident and CEO

At the same time, extremities, OMF, and Head and Neck, and other indications combined delivered solid 15% year-over-year growth through the first half. Adjusted net income was $7.3 million for the quarter. Adjusted EBITDA was $8.4 million, and we ended the period with $113.4 million in cash equivalents, restricted cash, and investments. Consistent with prior quarters, performance was driven by strong demand for Avance and continued adoption of our broader product algorithm across all target markets. Avance represented 65% of total revenue in the second quarter and 63% year to date, up from approximately 60% in 2025. Commercial execution remained strong across the business. Sales force productivity continued to exceed our expectations, and our active surgeon count increased meaningfully during the quarter, an indicator we monitor closely because it reflects broader institutional adoption of nerve care.

Michael DalePresident and CEO

We are also realizing the benefits of the sales force expansion investments we made throughout 2025 and the first half of 2026, as those representatives progress through their ramp and approach full productivity consistent with our market development model. Overall, these results reflect the strength of our commercial organization, the growing adoption of nerve care, and consistency in execution of our long-term growth strategy. Gross margin for the quarter was 72.7%, compared to 74.2% for the second quarter of 2025 and less than our plan. The shortfall was driven primarily by product mix, as breast growth accelerated faster than planned and relies more heavily on longer Avance grafts which carry higher production costs. Our manufacturing plans anticipated a growing breast business, not the relative change in revenue mix between our target markets that is now occurring, and the resulting impacts on longer graft product mix.

Michael DalePresident and CEO

We will address these changes in product mix through pricing actions and production efficiency initiatives. These measures will take time to implement, and as such, are unable to affect the remainder of our 2026 forecasted product mix. We are updating our 2026 gross margin guidance to be at least 73%. Looking forward, our operating bias remains to support growth in all target markets, while continuing to improve operating margin, EBITDA, and operating profits. Moving on to our second priority, market development across extremities, Oral and Maxillofacial, and Head and Neck, and breast. Consistent with prior quarters, each of our three target markets contributed positively to second quarter results.

Michael DalePresident and CEO

Extremities and OMF and head and neck both continued the steady progress we've described on prior calls, reflecting ongoing incremental surgeon activation and adoption of the AxoGen nerve repair algorithm, and continued account-level engagement, reflecting strong execution of our high-potential account development strategy. As mentioned earlier in my comments, year-to-date breast grew 47% year-over-year, driven by added commercial capacity, training of new surgeons, expansion of coverage and payment, and increasing surgeon and patient awareness. We believe we're still early in this market's development, even as it becomes a larger part of our overall mix. We now have roughly 215 active breast programs, an increase of over 40 programs year-over-year, and roughly 560 active surgeons, an increase of over 150 surgeons year-over-year.

Michael DalePresident and CEO

As a reminder of how we think about our markets longer term, each one sits at a different stage of development with different referral patterns, different training requirements, and different reimbursement dynamics. We outlined the size and potential of each prioritized market opportunity at our Analyst Day in March 2025. Second quarter and year-to-date results continue to reinforce the validity of this opportunity framework. We remain confident these markets can support double-digit growth for a long time as we continue to build the infrastructure, the evidence, and the awareness required to make nerve repair an expected standard of care. With regards to priority 3, commercial expansion, we ended the second quarter with a total commercial organization of 172 sales representatives, market development managers, and regional directors across all markets, consistent with our plan for disciplined, steady expansion of our commercial footprint.

Michael DalePresident and CEO

Year-to-date, we have added 15, including nine in extremities and six in breast, bringing those teams to 140 and 29 respectively, along with three dedicated market development managers in OMF and head and neck. We are very encouraged by our return on investment in sales force expansion. New representatives, those in their role for less than nine months, continue to contribute meaningfully to our growth. We believe these results validate one of our core assumptions, that expanding sales coverage is one of the most important levers within our control to affect market development and customer creation. The priority 4 of our strategic plan is commercial excellence, specific to our emphasis on high-potential accounts, productivity, and education. High-potential accounts continue to be a primary engine for our revenue growth, representing 60% of total revenue and 51% of growth year-to-date.

Michael DalePresident and CEO

Consistent with overall AxoGen growth, productivity in high-potential accounts was 20% year-over-year. The number of active high-potential accounts increased to 690, up 11 year-to-date. Non-high-potential accounts continue to grow as well, representing 40% of AxoGen's total revenue year-to-date and driving 24% year-over-year productivity per account. Growth in these accounts reflects growing awareness and adoption of nerve care in general. Active surgeon growth has increased by more than 210 year-to-date, with more than 135 added within high-potential accounts year-to-date. We have exceeded our plan for active surgeon growth in 2026. Regarding our professional education programs, year-to-date, we have conducted nine programs across all target markets, training 155 surgeons. Next, I'd like to update everyone on our priority 5, standard of care, evidence, and coverage development.

Michael DalePresident and CEO

As of today, commercial payer coverage for Avance is approximately 86% of covered lives in the United States. Aetna remains the largest commercial payer not yet covering Avance. Based on historical timing, we expected an update in June. However, Aetna's review is ongoing. If Aetna issues a favorable decision, we will consider that near universal commercial coverage in our existing markets in the United States, with approximately 95% of commercial lives with access to Avance. At that point, only a few regional payers and Humana will remain. Evidence generation remains a core pillar of our strategy to support development of nerve care guidelines and drive broader adoption of nerve repair and protection. This quarter, we advanced this strategy across multiple fronts. The recently published REPOSE study is an important example. REPOSE provides prospective, randomized clinical evidence evaluating AxoGuard Nerve Cap as an adjunct to standard neurectomy for symptomatic neuroma.

Michael DalePresident and CEO

The results reinforce the clinical rationale for protecting the nerve end after resection, with favorable signals in pain burden, medication reliance, and recovery-related outcomes over follow-up. Importantly, we view REPOSE as more than a study in one procedure. It strengthens the evidence foundation for our nerve protection portfolio and supports the broader clinical message that nerve management matters when surgeons are addressing pain, function, and quality of life. We are also advancing Nerve-RESTORE, our randomized assessor blinded study comparing Avance to sural nerve autograft in mixed and motor peripheral nerve reconstruction. This is strategically significant because autograft has long been viewed as the historical benchmark in complex nerve reconstructions. In Q2, we activated our first site in the United States and are screening for patients. We are on track for additional site activations in the second half of 2026.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day